Using National Registries to Identify Targeted Therapies for Refractory Urticaria
Int Arch Allergy Immunol
.
2021;182(5):459-460.
doi: 10.1159/000514689.
Epub 2021 Mar 9.
Authors
Sujoy Khan
1
,
Louise J Michaelis
2
,
Tom C Dawson
3
,
Anna Thusby-Pelham
4
,
Leyla Pur Özyiğit
5
,
Mamidipudi Thirumala Krishna
6
7
,
Mich Erlewyn-Lajeunesse
8
Affiliations
1
Immunology & Allergy, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Cottingham, United Kingdom, sujoykhan@gmail.com.
2
Paediatric Immunology, Allergy & Infectious Diseases, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.
3
Paediatric Department, Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom.
4
Department of Paediatrics, Bristol Royal Hospital for Children, Bristol, United Kingdom.
5
Department of Allergy, University Hospitals Leicester NHS Trust, Leicester, United Kingdom.
6
Department of Allergy and Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
7
Institute of Immunology and Immunotherapy and Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.
8
Paediatric Allergy & Immunology, Southampton Children's Hospital, Southampton, United Kingdom.
PMID:
33690233
DOI:
10.1159/000514689
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Chronic Urticaria*
Humans
Omalizumab / therapeutic use
Registries
Urticaria* / diagnosis
Urticaria* / drug therapy
Substances
Antibodies, Monoclonal, Humanized
Omalizumab
ligelizumab